KR20180124432A - Composition for improving acne with antioxidant, antibacterial and anti-inflammatory properties - Google Patents
Composition for improving acne with antioxidant, antibacterial and anti-inflammatory properties Download PDFInfo
- Publication number
- KR20180124432A KR20180124432A KR1020170058923A KR20170058923A KR20180124432A KR 20180124432 A KR20180124432 A KR 20180124432A KR 1020170058923 A KR1020170058923 A KR 1020170058923A KR 20170058923 A KR20170058923 A KR 20170058923A KR 20180124432 A KR20180124432 A KR 20180124432A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- improving acne
- acne
- extract
- improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 74
- 206010000496 acne Diseases 0.000 title claims abstract description 74
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 31
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 21
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 18
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract description 21
- 239000000284 extract Substances 0.000 claims abstract description 58
- IPRLELFMTNDNMN-UHFFFAOYSA-N DOD Natural products CCCCCCCCC(O)C=CC(O)CCCCCC(O)=O IPRLELFMTNDNMN-UHFFFAOYSA-N 0.000 claims abstract description 28
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims abstract description 17
- IPRLELFMTNDNMN-CCEZHUSRSA-N (e)-7,10-dihydroxyoctadec-8-enoic acid Chemical compound CCCCCCCCC(O)\C=C\C(O)CCCCCC(O)=O IPRLELFMTNDNMN-CCEZHUSRSA-N 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- -1 hydroxy fatty acids Chemical class 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 18
- 239000000194 fatty acid Substances 0.000 claims description 18
- 229930195729 fatty acid Natural products 0.000 claims description 18
- 241000186427 Cutibacterium acnes Species 0.000 claims description 16
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- 230000000845 anti-microbial effect Effects 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 229940055019 propionibacterium acne Drugs 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 9
- 239000000839 emulsion Substances 0.000 claims description 6
- FCBUKWWQSZQDDI-UHFFFAOYSA-N rhamnolipid Chemical compound CCCCCCCC(CC(O)=O)OC(=O)CC(CCCCCCC)OC1OC(C)C(O)C(O)C1OC1C(O)C(O)C(O)C(C)O1 FCBUKWWQSZQDDI-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000008279 sol Substances 0.000 claims 1
- 241000913776 Pueraria montana Species 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 37
- 230000000694 effects Effects 0.000 description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 238000002835 absorbance Methods 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 12
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000002292 Radical scavenging effect Effects 0.000 description 9
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 8
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 235000013824 polyphenols Nutrition 0.000 description 7
- 235000013599 spices Nutrition 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- 230000002421 anti-septic effect Effects 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical class [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000012488 sample solution Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003876 biosurfactant Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000009036 growth inhibition Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- ZTOKUMPYMPKCFX-CZNUEWPDSA-N (E)-17-[(2R,3R,4S,5S,6R)-6-(acetyloxymethyl)-3-[(2S,3R,4S,5S,6R)-6-(acetyloxymethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxyoctadec-9-enoic acid Chemical compound OC(=O)CCCCCCC/C=C/CCCCCCC(C)O[C@@H]1O[C@H](COC(C)=O)[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(C)=O)O1 ZTOKUMPYMPKCFX-CZNUEWPDSA-N 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000001263 FEMA 3042 Substances 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 241000234280 Liliaceae Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 2
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 2
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 2
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000017066 negative regulation of growth Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 2
- 229940033123 tannic acid Drugs 0.000 description 2
- 235000015523 tannic acid Nutrition 0.000 description 2
- 229920002258 tannic acid Polymers 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- QLLFQPUPUZJCBX-UHFFFAOYSA-N 3-ethyl-1-[(3-ethyl-6-sulfo-2H-1,3-benzothiazol-1-ylidene)hydrazinylidene]-2H-1,3-benzothiazole-6-sulfonic acid Chemical compound N(N=S1CN(C2=C1C=C(C=C2)S(=O)(=O)O)CC)=S1CN(C2=C1C=C(C=C2)S(=O)(=O)O)CC QLLFQPUPUZJCBX-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000233614 Phytophthora Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000704 biodegradable plastic Polymers 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002910 effect on acne Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- NKCCODPFBDGPRJ-UHFFFAOYSA-N nitridocarbon(1+) Chemical compound N#[C+] NKCCODPFBDGPRJ-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003924 oil dispersant Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000008265 rhamnosides Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 항산화, 항균 및 항염증 효능을 지닌 여드름 개선용 조성물에 관한 것으로, 보다 상세하게는 람노리피드(Rhamnolipids) 및 하이드록시 지방산(7,10-dihydroxy-8(E)-octadecenoic acid)을 포함하는 녹농균(Pseudomonas aeruginosa) 배양액 추출물을 유효성분으로 하는 항산화, 항균 및 항염증 효능을 지닌 여드름 개선용 조성물 및 이에 칡 잎 추출물을 더 포함하는 여드름 개선용 조성물에 관한 것이다.The present invention relates to a composition for improving acne with antioxidative, antibacterial and anti-inflammatory properties, and more particularly, to a composition for improving acne which comprises Rhamnolipids and 7,10-dihydroxy-8 (E) -octadecenoic acid. A composition for improving acne with antioxidant, antibacterial and antiinflammatory activity, which comprises an extract of Pseudomonas aeruginosa culture fluid as an active ingredient, and a composition for improving acne, which further comprises a leaf extract thereof.
피부미용 분야에서 여드름의 정확한 원인은 아직까지 밝혀져 있지 않으며 여러 인자의 상호작용에 의해 유발되기 때문에 현재까지 효과적인 단일 치료법은 없는 실정이다. 여드름은 특히 사춘기에 발생하며 면포, 구진, 농포, 결절 등의 병변을 특징으로 하는 모피지성 질환(pilosebaceous disease)으로 최근 성인에게도 여드름의 발생이 증가한다는 보고가 늘고 있다.The exact cause of acne has not yet been elucidated in the field of skin care and is caused by the interaction of several factors, so there is no single effective treatment until now. Acne is a pilosebaceous disease characterized by lesions such as cotton papules, papules, pustules, and nodules that occur particularly during puberty, and the incidence of acne has increased in recent adults.
서구 문명사회에서는 10대 청소년 인구의 약 79-95% 정도가 여드름 질환을 가지고 있고, 특히 미국에서는 4,000~5,000만 명 정도가 여드름 환자로 집계되고 있다. 이는 10대에 국한하지 않고, 어린이에서 성인에게 까지 널리 분포하고 있으며, 한 연구에서는 25세 이상의 성인 남자 중 40%, 성인 여자 중에는 54% 정도가 여드름성 질환 경험이 있다고 보고된 바도 있다. 여드름은 문명 사회의 피해갈 수 없는 대표적인 질환 중에 하나가 되었다.In Western civilized society, about 79-95% of teenagers have acne disease, and in the United States, about 4,000 to 50 million people are counted as acne patients. This is not limited to teenagers but is widely distributed among children and adults. In one study, 40% of adult men aged 25 or older and 54% of adult women reported experiencing acne. Acne became one of the major diseases that civilized society can not avoid.
여드름과 같은 피부질환의 병인으로 환경적요인, 식습관, 스트레스, 체력저하 등으로 인한 체내 자유라디칼(free radical)의 생성과 그에 따른 세포의 산화적 스트레스(oxidative stress)가 많이 연구되어 이해되고 있다. 인체의 세포에서 이용된 산소의 일부는 부분적으로 환원되어 활성산소로 변화하며 그로 인한 산화 스트레스는 세포에 자극을 주어 피부에서는 각종 질병과 피부질환의 원인이 되는 것으로 알려져 있다. As a pathogen of skin diseases such as acne, the production of free radicals due to environmental habits, eating habits, stress and physical strength, and the resulting oxidative stress of cells have been studied and understood. It is known that some of the oxygen used in human cells is partially reduced to active oxygen, and the resulting oxidative stress stimulates the cells to cause various diseases and skin diseases in the skin.
산화질소(NO, nitric oxide)는 고 반응성의 생체 생성 라디칼의 일종으로 neuronal NOS (nNOS), endothelial NOS (eNOS), inducible NOS (iNOS) 세가지 형태로 구성된 NOS (Nitric oxide synthase)에 의해 L-아르기닌(L-arginine)과 산소(O2)로부터 생성되는데 정상 생리 상태에서는 신경신호 전달 및 박테리아의 사멸을 통한 면역작용 등의 생리적으로 중요한 역할을 하지만, 과도하게 작용하면 생체의 염증을 유발시키고 유전자의 변이, 조직과 신경의 손상 등을 일으키며 인체에 해로운 작용을 하게 된다. Nitric oxide (NO) is a kind of highly reactive biogenic radical that is formed by NOS (Nitric Oxide Synthase) composed of three types of neuronal NOS (nNOS), endothelial NOS (eNOS) and inducible NOS (L-arginine) and oxygen (O 2 ). In normal physiological state, it plays a physiologically important role such as nerve signal transmission and immunity through the death of bacteria. Excessive action may cause inflammation of the living body, Mutations, damage to tissues and nerves, and so on.
또한 NO는 직·간접적으로 시클로옥시게나아제-2(COX-2, cyclooxygenase-2)의 활성을 조절하는데 직접적으로는 초과산화물 음이온 라디칼(superoxide anions radical)과 반응하여 ONOO- (peroxynitrite anions)을 생성하여 COX-2의 촉매적 활성을 증가시키며, 간접적으로는 signaling cascade를 촉발하여 전사단계에서 COX-2의 발현을 조절하는 것으로 알려져 있다. In addition, NO directly or indirectly regulates the activity of cyclooxygenase-2 (COX-2) and directly reacts with superoxide anions radicals to generate ONOO - (peroxynitrite anions) , Which increases the catalytic activity of COX-2 and indirectly triggers signaling cascade and regulates the expression of COX-2 in the transcription stage.
COX-2는 염증반응을 조절하는 중요인자 중 하나인 COX의 inducible isoform으로서 다양한 난치성 질환에 관여하며 병리학적 염증반응에서 급성적으로 발현되는 것으로 알려져 있다. 일반적으로 생체에서 염증 반응이 일어날 때에는 iNOS에 의해 NO가 다량 생성되며 COX-2의 발현이 증가되는 것으로 알려져 있기 때문에 iNOS와 COX-2의 생성을 억제하는 물질은 여드름을 포함한 염증반응의 조절제로서의 가능성이 높다고 알려져 있다.COX-2 is an inducible isoform of COX, which is one of the important factors controlling inflammatory response. It is involved in various intractable diseases and is known to be expressed acutely in pathological inflammatory reaction. In general, when the inflammatory reaction occurs in vivo, it is known that iNOS produces a large amount of NO and COX-2 expression is increased. Therefore, a substance that inhibits the production of iNOS and COX-2 is a potential modulator of inflammation including acne Is known to be high.
여드름의 다른 경로의 병인으로 남성호르몬에 의한 피지 분비의 증가, 과각화된 모낭벽의 증가, 프로피오니박테리움 아크네스(Propionibacterium acnes , P. acnes) 의 증식에 의한 염증유발, 피부장벽이상, 유전, 환경적 요인, 모낭의 반응성 등 복합적인 요인으로 발생한다. 이 중 여드름 발생의 중요한 원인은 여드름 유발균인 P.acnes 의 증식이다. P. acnes 는 혐기성 상재균으로서 모낭 내에서 성장하는 지방 친화성 미생물이다. 포도상구균(Staphylococus aureus, S. aureus) 와 표피포도상 구균(Staphylococcus epidermidis, S. epidermidis)는 피부 내에 정상적으로 분포하는 호기성 피부 상재균으로 염증의 일차적 원인은 아니지만, 염증 발생 부위를 더욱 확장 시켜 결국 여드름을 악화시킨다.The pathogenesis of other pathways of acne includes increased sebum secretion by male hormones, increased hair follicle walls, inflammation induced by proliferation of Propionibacterium acnes (P. acnes), skin barrier abnormalities, Environmental factors, and reactivity of hair follicles. The most important cause of acne is the proliferation of acne-causing P. acnes. P. acnes is a lipophilic microorganism that grows in the follicle as an anaerobic mantle. Staphylococcus aureus (S. aureus) and Staphylococcus epidermidis (S. epidermidis) are aerobic skin strains normally distributed in the skin and are not the primary cause of inflammation. However, Deteriorate.
여드름의 원인 중 세균 감염에 의해 생성되는 염증성 여드름의 경우 항생제 투여에 의해 증상을 개선할 수 있으나 여드름 치료에 주로 이용되는 테트라사이클린(tetracycline), 클린다마이신(clindamycin), 에리트로마이신(erythromycin)을 장기간 사용 했을 때 부작용을 유발하거나 내성이 발생하여 치료효과가 떨어질 수 있다. 또한 여드름 형성 억제를 위해 강력한 면포 용해 기능을 가지는 레티노이드(retinoids)와 P. acnes 증식 억제 목적의 항생제를 병용하는 방법은 치료효과를 증진시킬 수는 있으나 부작용 또한 증가시키는 단점이 있다.Inflammatory acne caused by bacterial infection among the causes of acne can be ameliorated by the administration of antibiotics. However, long-term use of tetracycline, clindamycin, and erythromycin, which are mainly used in the treatment of acne, , It may cause side effects or resistance, resulting in decreased therapeutic efficacy. In addition, the combination of retinoids, which have a strong solubilization function for inhibiting acne formation, and antibiotics for the inhibition of P. acnes proliferation may improve the therapeutic effect but also increase the side effects.
화장품에 사용되는 항균제는 필수적이지만 기존에 사용되고 있는 합성 물질들은 피부에 알러지를 유발할 수 있으므로 여드름 피부에 효과적이고 피부에 안전하고 부작용을 최소화할 수 있는 천연물 탐색을 위한 연구가 요구되고 있고, 천연 항균물질에 대한 관심도 급증하고 있는 추세이다.Although antimicrobial agents used in cosmetics are essential, synthetic materials used in the past can cause allergies to the skin. Therefore, research for searching natural products that are effective for acne skin, safe for skin and minimized side effects is required, and natural antimicrobial Interest in the market is also increasing rapidly.
따라서, 인체에 안전하면서도 여드름 피부에 대한 개선효과가 우수한 제품의 개발 필요성이 꾸준히 대두되고 있는 상황이다.Therefore, there is a need to develop a product that is safe for human body and has excellent improvement effect on acne skin.
본 발명은 전술한 문제점을 개선하여 항산화, 항균 및 항염증 효능을 지닌 여드름 개선용 조성물을 제공하는 것을 목적으로 한다.It is an object of the present invention to provide a composition for improving acne with antioxidant, antibacterial and anti-inflammatory properties by solving the above-mentioned problems.
또한, 본 발명은 여드름 치료, 예방 또는 개선을 위한 여드름 개선용 화장료 조성물, 여드름 개선용 피부외용제 조성물 및 여드름 개선용 식품 조성물을 제공하는 것을 목적으로 한다.It is still another object of the present invention to provide a cosmetic composition for improving acne, a composition for external application for improving acne, and a composition for improving acne for treating, preventing or improving acne.
본 발명은 람노리피드 및 하이드록시 지방산을 포함하는 녹농균 배양액 추출물을 유효성분으로 하는 항산화, 항균 및 항염증 효능을 지닌, 여드름 개선용 조성물을 제공한다.The present invention provides an antioxidant, antimicrobial and anti-inflammatory effect composition for improving acne comprising an extract of Pseudomonas aeruginosa culture solution containing rhamnose and hydroxy fatty acid as an active ingredient.
본 발명은 상기 여드름 개선용 조성물에 칡 잎 추출물을 더 포함하는 것을 특징으로 하는 여드름 개선용 조성물을 제공한다.The present invention also provides a composition for improving acne characterized by further comprising a mulberry leaf extract in the composition for improving acne.
본 발명의 여드름 개선용 조성물은 화학적 항생제를 사용하지 않는 천연물 유래의 항산화, 항균 및 항염증 효능을 지닌, 여드름 개선용 조성물로 인체에 부작용이 없으면서 여드름 완화 효과를 갖는다.The composition for improving acne according to the present invention has antioxidative, antibacterial and anti-inflammatory properties derived from natural materials without using a chemical antibiotic, and has an acne-reducing effect without side effects on the human body.
본 발명의 여드름 개선용 조성물은 여드름 원인균에 대한 항균 활성이 우수하여, 여드름에 대한 예방 및 개선 효과가 우수하며, 화장료, 식품 또는 피부외용제 조성물 등으로 이용될 수 있다.The composition for improving acne according to the present invention is excellent in antimicrobial activity against acne causing bacteria and has excellent prevention and improvement effect against acne and can be used as a cosmetic, food or skin external composition composition.
도 1은 람노리피드와 DOD를 동시에 함유하는 물질의 7종의 피부상재균에 대한 항균효과를 측정 한 것으로서, 측정 사진과 생육저해환을 측정한 표와 함께 나타내었다.
도 2는 상기 알파벳에 따른 항목은 실험에 사용된 균주의 이름을 나타낸다.
도 3은 람노리피드와 DOD를 동시에 함유하는 물질이 생육저해환 측정 실험에서 효과를 나타낸 표피포도상 구균(Staphylococcus epidermidis)에 대한 MIC 테스트의 결과이다.
도 4는 람노리피드와 DOD를 동시에 함유하는 물질이 생육저해환 측정 실험에서 효과를 나타낸 프로피오니박테륨아크네스(Propionibacterium acnes)균에 대한 MIC 테스트의 결과이다.
도 5는 칡 잎 추출물의 DPPH 라디칼 소거능 측정 결과이다.
도 6은 칡 잎 추출물의 ABTS 라디칼 소거능 측정 결과이다.
도 7은 칡 잎 추출물의 총 폴리페놀 함량(total polyphenolic contents) 측정 결과이다.
도 8은 칡 잎 추출물의 농도에 따른 대식세포(Raw264.7)의 세포 생존률 측정 결과이다.
도 9는 칡 잎 추출물의 농도에 따른 대식세포(Raw264.7)에서의 Nitric oxide 생성 억제 효능 측정 결과이다.
도 10은 칡 잎 추출물의 농도에 따른 대식세포(Raw264.7)에서의 iNOS, COX-2 단백질 발현 억제 효능 측정 결과이다Fig. 1 shows antimicrobial effects of seven kinds of dermatophytes of rumorifide and DOD at the same time. The photographs are shown together with the measured photographs and the measured inhibition rings.
2 shows the names of the strains used in the experiment.
Fig. 3 shows the result of MIC test for Staphylococcus epidermidis, which exhibited the effect of a substance containing both Ramanolipid and DOD in a growth inhibition ring assay.
Fig. 4 is a result of MIC test on Propionibacterium acnes showing the effect of a substance containing both Ramanoride and DOD in the growth inhibition assay.
FIG. 5 shows the DPPH radical scavenging activity of the extract of Liliaceae.
FIG. 6 shows the results of ABTS radical scavenging ability measurement of the 칡 leaf extract.
Fig. 7 shows the results of measurement of total polyphenolic contents of Leaf leaf extract.
FIG. 8 shows the results of measurement of cell viability of macrophages (Raw264.7) according to the concentration of Leaf leaf extract.
FIG. 9 shows the results of measurement of the inhibitory effect of Nitric oxide formation on macrophage (Raw 264.7) according to the concentration of Leaf leaf extract.
FIG. 10 shows the results of measuring the inhibitory effect of iNOS and COX-2 protein expression on macrophages (Raw 264.7) according to the concentration of 칡 leaf extract
이하, 본 발명에 대하여 상세하게 설명하도록 한다.Hereinafter, the present invention will be described in detail.
본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현 가능하다.The present invention is not limited to the embodiments described below, but can be embodied in various other forms.
아래 열거된 정의는 본 발명을 기술하기 위해 사용된 다양한 용어들의 정의이다. 이들 정의는 달리 제한되지 않는 한, 단지 특정한 실시예를 설명하기 위해 사용된 것으로, 본 발명을 한정하려는 의도가 아니다.The definitions listed below are definitions of various terms used to describe the present invention. These definitions are used to describe only specific embodiments, unless otherwise limited, and are not intended to limit the invention.
본 발명은 화학적 항생제를 사용하지 않는 천연물 유래의 항산화, 항균 및 항염증 효능을 지닌, 여드름 개선용 조성물에 관한 것으로, 녹농균의 균주로부터 배양되어 추출된 생물 계면활성제 및 하이드록시 지방산과 식물성 천연물질(칡 잎 추출물)의 혼합물을 포함한 것이다.The present invention relates to a composition for improving acne with antioxidative, antibacterial and anti-inflammatory properties derived from natural materials without using chemical antibiotics. The composition comprises a biosurfactant extracted from a strain of Pseudomonas aeruginosa, Leaf extract).
생물계면활성제(Biosurfactant)는 화학합성 계면활성제에 비해 물리, 화학적 성능면에서 대등한 특성을 나타내지만 무독성이며 생분해가 용이한 친환경계면활성제로서 산업적으로 유용한 소재이다.Biosurfactant is an industrially useful material that is comparable in chemical and physical properties to chemically synthesized surfactants but is non-toxic and easy to biodegrade as an environmentally friendly surfactant.
소포로리피드는 당지질(glycolipid) 계열의 미생물계면활성제로서, 소포로리피드가 갖는 물질적 생리적 특성으로 인해 세제 및 유류분산제로 사용이 가능하고, 여드름균을 비롯한 그람양성균에 높은 항균효과를 보이지만 일반 항생제와 달리 인체에 부작용이 거의 없으며 내성문제를 야기하지 않고 생분해가 뛰어나다. Sophorolipid is a glycolipid-based microbial surfactant that can be used as a detergent and an oil dispersant due to the physical and physiological properties of sophorolipid and has high antimicrobial activity against Gram-positive bacteria including acne bacteria. Otherwise, there is little side effect on the human body, and it does not cause resistance problem and is excellent in biodegradation.
소포로리피드 중 람노리피드의 경우 일부 슈도모나스 균주에 의해 생산되는 것이 알려져 있으며 우수한 분산능력, 그람양성 미생물에 대한 항균효과를 보이는 것으로 보고되고 있어 고급 생물계면활성제로 개발되고 있다.In the case of the soporolipid, rhamnolipid is known to be produced by some Pseudomonas strains and has been reported to exhibit excellent dispersing ability and antimicrobial activity against Gram-positive microorganisms, and is being developed as a high-grade biosurfactant.
전세계 계면활성제 시장은 1990년대 초부터 년 50% 이상의 급속한 성장세로 증가하여 왔으며 그 수요는 계속해서 증가하고 있다. 생물계면활성제의 경우 제품특성에 따라 화장품, 의약품, 식품, 세제, 펄프 및 제지, 환경정화 등 친환경분야에 적용할 수 있는 분야가 다양하여 그 수요가 크게 증가하고 있는 추세이다. The worldwide surfactant market has been growing at a rapid rate of more than 50% a year since the early 1990s, and the demand is steadily increasing. In the case of biosurfactants, the demand for environmentally friendly products such as cosmetics, pharmaceuticals, foods, detergents, pulp and paper, and environmental purification varies depending on product characteristics.
하이드록시 지방산(Hydroxy fatty acid, HFA)은 일반 지방산의 중심사슬에 1개 이상의 하이드록실기를 갖고 있는 형태로, 지방산 사슬에 추가적으로 붙어 있는 하이드록실기에 의해 지방산으로 하여금 높은 점성이나 반응성 등 특이한 성질을 갖도록 한다. 하이드록시 지방산은 연결되어 있는 하이드록실기의 수에 따라 모노-(mono-), 다이-(di-), 트리-(tri-)하이드록시 지방산으로 분류되며, 하이드록실기 외에 별도의 구조를 포함하는 에폭시하이드록시 지방산(epoxy-hydroxy fatty acid)이나 옥소하이드록시 지방산(oxo-hydroxy fatty acid) 등도 포함한다.Hydroxy fatty acid (HFA) is a form that has at least one hydroxyl group in the central chain of a common fatty acid. The hydroxyl group added to the fatty acid chain gives the fatty acid a unique property such as high viscosity and reactivity . Hydroxy fatty acids are classified into mono-, di-, and tri- (hydroxy) fatty acids depending on the number of hydroxyl groups to which they are attached and include a separate structure in addition to the hydroxyl group Or an epoxy-hydroxy fatty acid or an oxo-hydroxy fatty acid.
하이드록시 지방산은 자연계에서 주로 식물체에서 미량으로 발견되고 있지만 하이드록시 지방산에 도입된 하이드록실기에 의해 지방산으로 하여금 높은 점성이나 반응성 등 특이한 성질을 부여하게 되어 산업적으로 다양한 분야에 이용될 수 있다. 그 결과 농약, 의약, 고기능성 레진 및 섬유소재, 생분해성 플라스틱 소재, 윤활제, 화장품, 페인트 등 산업 전반에 광범위하게 응용될 수 있다.Hydroxy fatty acids are found in trace amounts in plants mainly in nature. However, hydroxy groups introduced into hydroxy fatty acids give fatty acids with specific properties such as high viscosity and reactivity, and thus they can be used in various industrial fields. As a result, it can be widely applied to various industries such as pesticides, medicines, high-functional resins and fiber materials, biodegradable plastic materials, lubricants, cosmetics and paints.
칡은 다년생 식물로 오래전부터 구황작물로 식용되었고 자양강장제 등 건강식품으로 이용되기도 하였다. 한방에서는 뿌리를 갈근(葛根)이라는 약재로 쓰는데 발한, 해열 등의 효과가 있다고 알려져 있다. 최근에는 칡의 용도가 한정되는 경향이며 관련된 연구 또한 뿌리에 치중되어 진행되고 있으며, 칡 잎의 피부약리학적 효능에 관해 연구된 국내논문과 특허는 매우 적다.칡 is a perennial plant that has been eaten as a wild plant since long ago and has been used as a health food such as nourishing tonic. In the oriental medicine, it is said that the roots are used as a medicinal substance called 葛根, and it is said to have effects such as perspiration and fever. In recent years, there has been a tendency that the use of 칡 is limited, and the related research is also focused on the root, and domestic papers and patents about the skin pharmacological efficacy of 칡 leaf are very few.
본 발명은 람노리피드(Rhamnolipids) 및 하이드록시 지방산(7,10-dihydroxy-8(E)-octadecenoic acid )을 포함하는 녹농균(Pseudomonas aeruginosa) 배양액 추출물을 유효성분으로 하는 항산화, 항균 및 항염증 효능을 지닌, 여드름 개선용 조성물을 제공한다. The present invention relates to an antioxidant, antimicrobial and anti-inflammatory agent comprising, as an active ingredient, a Pseudomonas aeruginosa culture liquid extract containing Rhamnolipids and 7,10-dihydroxy-8 (E) -octadecenoic acid The composition for improving acne is provided.
본 발명에서는 슈도모나스에어루지노사(KACC 10186)균을 배양하는 것으로 여드름균등에 항균효과를 가지는 DOD (7,10-dihydroxy-8(E)-octadecenoic acid)와 람노리피드(Rhamnolipids)가 함께 함유되어 있는 배양액을 만들고 그 추출물을 사용하였다. In the present invention, by culturing Pseudomonas aeruginosa (KACC 10186), DOD (7,10-dihydroxy-8 (E) -octadecenoic acid) and Rhamnolipids, which have antimicrobial activity against acne, And the extract was used.
본 발명은 슈도모나스에어루지노사균의 배양액 추출물중 기존에 알려져 있던 물질 람노리피드이외에 여드름균에 효과가 있는 DOD가 존재하는 것을 알아내었다.The present invention has found that DOD, which is effective for acne bacteria, is present in addition to the conventionally known substance rhamnolipid among the Pseudomonas aeruginosa culture extract.
이는 장기간 사용했을 때 부작용을 유발하거나 내성이 생기는 기존의 여드름 치료 물질 테트라사이클린(tetracycline), 클린다마이신(clindamycin), 에리트로마이신(erythromycin) 등의 단점을 보완하고 여타 합성 항균물질의 부작용으로 알려져 있는 알러지등을 방지할 수 있는 장점을 가지고 있으며 생분해가 용이하여 산업적으로 유용한 소재이다. This is the traditional acne remedy that causes side effects or resistance when used for a long time. It is complementary to the disadvantages of tetracycline, clindamycin, erythromycin and allergies known as side effects of other synthetic antimicrobials. And it is industrially useful material because it is easily biodegradable.
본 발명의 일 구현예에서, 상기 여드름 개선용 조성물은 칡 잎 추출물을 더 포함하는, 여드름 개선용 조성물일 수 있다.In one embodiment of the present invention, the composition for ameliorating acne may be a composition for improving acne, which further comprises a lupine extract.
보다 나은 조성물로의 개발을 위해 본 발명의 상기 녹농균 배양액 추출물에, 약리학적 실험으로 항산화, 항염증 효과를 검증한 칡 잎 추출물을 첨가하여 여드름 개선 효능의 상승을 도모하였다.In order to develop a better composition, the extract of P. aeruginosa culture solution of the present invention is enhanced by adding phytophthora extract obtained by pharmacological experiment, which has been proved to have antioxidant and anti-inflammatory effects.
칡 잎 추출물은 강력한 항산화 작용과 항염증 작용을 하는 천연물질로서 인체 내부에서 세포에 자극을 주며 피부에서는 각종 질병과 피부질환의 원인이 되는 산화적 스트레스를 억제시키고 과도하게 작용하면 유전자의 변이, 조직과 신경의 손상 등을 일으키며 인체에 해로운 작용을 하는 염증현상을 조절하는 작용을 한다.칡 Leaf extract is a natural substance that has a strong antioxidant and anti-inflammatory action. It stimulates the cells inside the human body. It suppresses oxidative stress that causes various diseases and skin diseases in the skin. If it acts excessively, And damage the nervous system, and acts to control the inflammatory phenomenon that is harmful to human body.
본 발명에 따른 칡 잎 추출물은 칡 잎을 유기용매로 추출하여 얻을 것을 말한다.The 칡 leaf extract according to the present invention is obtained by extracting 칡 leaf with an organic solvent.
람노리피드와 하이드록시 지방산이 동시 생성되는 녹농균 배양액 추출물에 칡 잎 추출물을 혼합하여 조성물화 함으로서 효능에 대한 상승효과를 볼 수 있으며 항산화, 항균, 항염증 작용을 고르게 하므로 사용범위가 넓고 효과적이다.By combining the extract of Pseudomonas aeruginosa with the extract of P. aeruginosa cultivated with the simultaneous production of rhamniripid and hydroxy fatty acid, the synergistic effect on the efficacy can be seen, and the antioxidant, antibacterial and antiinflammatory action can be uniformly used.
본 발명에 따른 슈도모나스에어루지노사(KACC 10186)균의 배양액 추출물중 모노람노리피드(mono- rhamnolipids)는 화학식1로 표시되며 DOD (7,10-dihydroxy-8(E)-octadecenoic acid)는 화학식2로 표시된다:Mono-rhamnolipids of the culture solution of Pseudomonas aeruginosa (KACC 10186) according to the present invention are represented by the formula (1), and DOD (7,10-dihydroxy-8 (E) -octadecenoic acid) 2:
[화학식 1][Chemical Formula 1]
[화학식 2](2)
본 발명의 일 구현예에서, 표피포도상 구균(Staphylococcus epidermidis) 또는 프로피오니박테륨아크네스(Propionibacterium acnes)에 대하여 항균 활성을 나타내는 것을 특징으로 하는, 여드름 개선용 조성물일 수 있다.In one embodiment of the present invention, it may be a composition for improving acne characterized by exhibiting an antibacterial activity against Staphylococcus epidermidis or Propionibacterium acnes.
본 발명의 일 구현예에서, 상기 람노리피드와 하이드록시지방산을 1: 0.1 내지 0.8의 중량비로 포함하는, 여드름 개선용 조성물일 수 있다.In one embodiment of the present invention, it may be a composition for improving acne, which comprises the rhamnolipid and the hydroxy fatty acid at a weight ratio of 1: 0.1 to 0.8.
본 발명의 일 구현예에서, 람노리피드와 하이드록시 지방산이 동시 생성되는 녹농균 배양액 추출물을 유효성분으로 하는 상기 여드름 개선용 조성물은 당해 조성물의 전체 중량을 기준으로 0.001 내지 20 중량부의 함량으로 포함되는 것을 특징으로 하는, 여드름 개선용 조성물일 수 있다.In one embodiment of the present invention, the acne improvement composition comprising the extract of a culture solution of P. aeruginosa in which rhamnose and hydroxy fatty acid are simultaneously produced is contained in an amount of 0.001 to 20 parts by weight based on the total weight of the composition Or a composition for improving acne.
본 발명의 일 구현예에서, 녹농균 배양액 추출물과 칡 잎 추출물의 사용 비율은 특별히 한정되지 않으며, 예를 들면 1: 0.5내지 30의 비로 포함될 수 있다. 함량비가 상기 범위 내인 경우 항산화, 항균 및 항염증 효능을 극대화할 수 있다.In one embodiment of the present invention, the use ratio of the extract of Pseudomonas aeruginosa culture and the extract of Liliaceae is not particularly limited and may be, for example, in a ratio of 1: 0.5 to 30. When the content ratio is within the above range, the antioxidant, antibacterial and anti-inflammatory effects can be maximized.
본 발명의 일 구현예에서, 상기 람노리피드와 하이드록시 지방산이 동시 생성되는 녹농균 배양액 추출물에 칡 잎 추출물을 더 포함하는 여드름 개선용 조성물은 당해 조성물의 전체 중량을 기준으로 0.001 내지 20 중량부의 함량으로 포함되는 것을 특징으로 하는 여드름 개선용 조성물일 수 있으며, 바람직하게는 1 내지10 중량부, 보다 바람직하게는 5 내지 10 중량부로 포함될 수 있다. 함량이 0.0001 중량부 미만인 경우에는 여드름 치료, 예방 및 개선 효과가 미약하고, 20 중량부를 초과하는 경우에는 함량의 증가에 따른 효과의 증가가 미비하고 제형상의 안정성이 확보되지 않는 문제점이 있다.In one embodiment of the present invention, the composition for improving acne, which further comprises a fungus leaf extract in the extract of the Pseudomonas aeruginosa culture solution in which the rhamnolipid and the hydroxy fatty acid are co-produced, comprises 0.001 to 20 parts by weight The composition for improving acne is preferably 1 to 10 parts by weight, more preferably 5 to 10 parts by weight. When the content is less than 0.0001 part by weight, the effect of treating, preventing and improving acne is insufficient. When the content is more than 20 parts by weight, the effect of increasing the content is not increased and the stability of the shape is not secured.
본 발명의 일 구현예에서, 상기 여드름 개선용 조성물은 여드름 개선용 화장료 조성물, 여드름 개선용 식품 조성물 또는 여드름 개선용 피부외용제 조성물일 수 있다.In one embodiment of the present invention, the composition for improving acne may be a cosmetic composition for improving acne, a composition for improving acne, or a composition for external application for improving acne.
본 발명에 따른 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있다. 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화 될 수 있으나, 이에 한정되는 것은 아니다.The composition according to the present invention can be prepared into any formulation conventionally produced in the art. For example, they may be formulated as solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations and sprays, But is not limited thereto.
이하에서는 본 발명의 구체적인 실시예들을 제시한다. 그러나 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되지 않는다.Hereinafter, specific embodiments of the present invention will be described. The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.
<< 준비예Preparation Example 및 And 실험예Experimental Example >>
[[ 준비예Preparation Example 1] One] 람노리피드와Randomized DOD를 동시에 함유하는 물질의 제조 Preparation of a substance containing DOD at the same time
1-1. 슈도모나스에어루지노사 KACC 10186 균주의 배양1-1. Culture of Pseudomonas aeruginosa KACC 10186 strain
슈도모나스에어루지노사 KACC 10186 균주를 이용하여 식물성오일을 기질로 모노람노리피드 및 다이하이드록시지방산을 공동생산하기 위하여, 다음과 같은 배양조건으로 생산하였다.Pseudomonas aeruginosa KACC 10186 strain was produced under the following culture conditions for the co-production of monoramnolipid and dihydroxy fatty acid with vegetable oil as a substrate.
슈도모나스에어루지노사 KACC 10186 균주를 M-NB 배지(0.7% 글리세롤, 0.1% 육추출물(beef extract), 0.2% 효모 추출물, 0.5% 펩톤, 0.5% 염화나트륨(NaCl), 0.02% 황산마그네슘(MgSO4)에서 30℃ 조건하에 배양하였다. Pseudomonas air Rouge labor KACC 10186 to M-NB medium (0.7% glycerol, 0.1% meat extract (beef extract), 0.2% yeast extract, 0.5% peptone, 0.5% sodium chloride (NaCl), 0.02% magnesium sulfate strain (MgSO 4) Lt; RTI ID = 0.0 > 30 C. < / RTI >
M-NB 배지에서 24 시간 배양한 KACC 10186 균주 배양액에 기질로서 1% 올리브유를 첨가하고 추가적으로 배양한 후 종료하였다. 배양 종료 후 동량의 에틸아세테이트를 첨가하여 상층액을 추출한 뒤 추출물을 회전증발기를 사용하여 농축하였다. 1% olive oil was added as a substrate to the culture medium of KACC 10186, which was cultured in M-NB medium for 24 hours, and further cultured and terminated. After the completion of the incubation, the same amount of ethyl acetate was added to extract the supernatant, and the extract was concentrated using a rotary evaporator.
상기와 같은 과정을 통해 수득된 조추출물에는 항균활성소재인 7,10-다이하이드록시-8(E)-옥타데세노산(7,10-dihydroxy-8(E)-octadecenoic acid, DOD) 및 모노람노리피드가 포함된다.The crude extract obtained through the above procedure contains 7,10-dihydroxy-8 (E) -octadecenoic acid (DOD), which is an antibacterial active material, and mono Randomized feeds are included.
1-2. 조추출물의 부분정제 (산성화 방법)1-2. Partial purification of crude extract (acidification method)
농축한 조추출물을 증류수와 1: 5의 비율로 섞은 다음 5N 염산(HCl)을 첨가하여 용액의 pH를 2-4로 만들어준 후 4 ℃에서 24 시간 보관하여 침전하였다. 침전물과 상층액을 분리한 후 헥산을 침전물과 혼합하여 람노리피드를 추출한 후 회전증발기를 이용하여 농축하였다. 이 후 동결건조를 이용해 시료를 분말화하여 실험을 진행하였다. The concentrated crude extract was mixed with distilled water at a ratio of 1: 5, and then the pH of the solution was adjusted to 2-4 by adding 5N hydrochloric acid (HCl), followed by storage at 4 ° C for 24 hours. After the precipitate and the supernatant were separated, hexane was mixed with the precipitate to extract the rhamnolipid and then concentrated using a rotary evaporator. After that, the sample was pulverized by freeze-drying to conduct the experiment.
[[ 준비예Preparation Example 2] 칡 잎 추출물의 제조 2] Production of 칡 leaf extract
칡 잎 추출물은 칡 잎을 음지에서 건조하여 잘게 부순뒤 중량의 20배의 70% 에탄올을 용매로 하여 상온에서 24시간 침지시켜 추출하는 과정을 3회 반복한 뒤 추출액을 여과지로 여과, 감압 농축, 동결 건조하여 분말화 하였다. 보관은 4 ℃ 냉장실에 보관하며 실험의 시료로 사용하였다.The extracts were prepared by filtration through a filter paper, concentrated under reduced pressure, and then concentrated under reduced pressure. The extracts were washed three times with distilled water and dried at room temperature for 24 hours using 70% And lyophilized to be powdered. Storage was kept in a 4 ° C refrigerator room and used as a test sample.
[[ 실험예1Experimental Example 1 ] ] 람노리피드와Randomized DOD를 동시에 함유하는 물질의 항균효과 Antibacterial effect of substances containing DOD at the same time
1-1. 균의 배양1-1. Culture of bacteria
람노리피드와 DOD를 동시에 함유하는 물질의 항균 효과를 알아보기 위해 7종의 균주를 생육하여 실험에 사용하였다.In order to investigate the antimicrobial effect of substances containing both ranorifide and DOD, seven strains were grown and used in the experiment.
칸디다 알비칸스(Candida albicans) 균은 25 ℃, 5% 이산화탄소 항온기(CO₂incubator)에서 배양하였다. 황색포도상구균(Staphylococcus aureus), 표피포도상 구균(Staphylococcus epidermidis), 녹농균(Pseudomonas aeruginosa), 프로피오니박테륨아크네스(Propionibacterium acnes), 대장균(Escherichia coli), 엔테로박터클로아케(Enterobacter cloacae) 균은 37 ℃, 5% CO₂incubator에서 배양하였다.Candida albicans were cultured in a 5
1-2. 1-2. 생육저해환Inhibition of growth 측정 Measure
항균력측정은 평판 디스크(paper disc agar diffusion)법으로 측정하였다. 고체 평판배지에서 배양된 각 균주를 1 백금이 취해서 액체배지 10 mL에 접종하여 18 ~ 24 h 배양시켜 활성화 시킨 후 다시 액체배지 10 mL에 균액을 0.1 mL접종하여 3 ~ 6 h 본배양한 후 고체 평판배지에 균수가 약 1 ? 107개가 되도록 멸균면봉으로 균일하게 도말하였다. The antimicrobial activity was measured by a paper disc agar diffusion method. Each of the strains cultured on the solid plate culture medium was inoculated into 10 mL of liquid culture medium by inoculating 1 mL of the culture medium for 18-24 h and then inoculated with 10 mL of the culture broth in 0.1 mL of the culture broth for 3-6 h, The number of bacteria on the plate medium is about 1? 10 7 < / RTI >
그후 멸균된 페이퍼 디스크(Paper disc)를 고체 평판배지에 올려놓은 다음 농도별로 희석된 시료용액을 디스크당 0.05mL 흡수시키고 각 균에 맞는 조건의 항온기(incubator)에서 24 ~ 72 시간 배양하여 페이퍼 디스크 주위의 클리어존(clear zone) (mm)의 직경을 측정하였다.After the sterilized paper disc was placed on a solid plate medium, 0.05 mL of the diluted sample solution was absorbed per disc and incubated for 24 to 72 hours in an incubator under conditions suitable for each microorganism. The diameter of the clear zone (mm) of the sample was measured.
1-3. 1-3. MICMIC 테스트 Test
7종의 균주 중 항균력을 가지는 2종 표피포도상 구균(Staphylococcus epidermidis), 프로피오니박테륨아크네스(Propionibacterium acnes) 의 람노리피드 최소억제농도(Minimal Inhibitory Concentration)를 알기위해 실험을 진행하였다. 균은 고체 평판 배지에서 배양된 각 균주 1을 백금으로 취해서 액체배지 10mL에 접종하여 18 ~ 24 시간 배양시켜 활성화시키고 이어서 액체배지 10mL에 균액을 0.1 mL 접종하여 3 ~ 6 시간 본 배양 한 것을 사용하였다. 실험에 사용된 각각의 균은 수가 약 1 x 106개가 되도록 만든 후 액체배지에 10-1씩 희석하여 사용하였다. 실험에 사용한 람노리피드는 0.01%, 0.02%, 0.04%, 0.08%, 0.16%, 0.31%, 0.63%, 1.25%, 2.5% 농도로 희석하여 사용하였다. 96홈판(96 well plate) 에 각 균의 적정 배지를 한 칸당 100μL 씩 분주한 후 대조군은 균, 실험군은 람노리피드를100 μL넣은뒤0h, 4h, 8h, 16h, 20h, 24h 의 간격으로 600nm에서 흡광도를 측정하였다.Staphylococcus epidermidis (Staphylococcus epidermidis), which has antibacterial activity among seven strains, Propionibacterium acnes (Propionibacterium acnes) The experiment was conducted to determine the minimum inhibitory concentration (RAM) concentration of the test compound. Bacteria were obtained by inoculating 1 ml of each
2-1. 2-1. 생육저해환Inhibition of growth 측정 결과 Measurement result
다양한 균주(Escherichia coli, Enterobacter cloace, Staphylococcus epidermidis, Pseudomonas auruginosa, Stapylococcus aureus, Propionibacterium acnes, Candida albicans)를 이용하여 람노리피드와 DOD 동시생성물의 항균효과를 측정하였다. Antimicrobial activities of co - products of Randomized and ROD were measured using various strains (Escherichia coli, Enterobacter cloace, Staphylococcus epidermidis, Pseudomonas auruginosa, Stapylococcus aureus, Propionibacterium acnes, Candida albicans).
그 결과 0.5 mg/disc 조건일때 모낭염의 원인이 되는 표피포도상 구균(Staphylococcus epidermidis)균에 대한 클리어존이 20 mm로 측정이 되었고 여드름 원인균인 프로피오니박테륨아크네스(Propionibacterium acnes) 균에 대한 클리어존이 21mm로 측정되어 이 균들에 대해 매우 뛰어난 항균효과가 있음을 확인하였다.As a result, the clear zone for Staphylococcus epidermidis was measured at 20 mm at 0.5 mg / disc condition, and Propionibacterium acnes, a causative agent of acne, The clear zone for the bacteria was measured to be 21 mm, confirming the excellent antibacterial effect against these fungi.
2-2. 2-2. MICMIC 테스트 결과 Test results
람노리피드와 DOD 동시생성물의 균에 대한 최소억제농도(Minimal Inhibitory Concentration)를 확인하기 위하여 MIC 테스트를 진행하였다. 생육저해환 측정실험에서 효과가 확인된 표피포도상 구균(Staphylococcus epidermidis), 프로피오니박테륨아크네스(Propionibacterium acnes)균에 대한 실험을 한 결과, 표피포도상 구균(Staphylococcus epidermidis)의 최소 억제농도는 0.16%, 프로피오니박테륨아크네스(Propionibacterium acnes)균의 최소 억제농도는 0.02%로 나타났다.The MIC test was conducted to confirm the minimal inhibitory concentration of the co-products of Randomized and DOD. Staphylococcus epidermidis, Staphylococcus epidermidis, Staphylococcus epidermidis, Experiments on Propionibacterium acnes showed that the minimum inhibitory concentration of Staphylococcus epidermidis was 0.16% and the minimum inhibitory concentration of Propionibacterium acnes was 0.02 %.
[[ 실험예2Experimental Example 2 ] 칡 잎 추출물의 항산화 효과] Antioxidative Effect of Leaf Extracts
1-1. 1-1. DPPHDPPH 라디칼 Radical 소거능Scatters
DPPH 라디칼 소거활성(radical scavenging)을 이용한 항산화 효과의 측정은 Blois의 방법에 따라 측정하였다. 각 시료용액 120 μL에 0.45 mM의 2,2-디페닐-1-피크릴히드라질(picrylhydrazyl) (DPPH) 60 μL를 넣고 15 분 동안 반응시킨 후 517 nm 에서 흡광도를 측정하여 결과를 계산하였다. The antioxidative effect of DPPH radical scavenging was measured by Blois method. To 120 μL of each sample solution, 60 μL of 0.45
DPPH 라디칼 소거능(%) = (1-시료첨가군 흡광도/무첨가군 흡광도)×100DPPH radical scavenging ability (%) = (1-absorbance group in the sample addition group / absorbance in the no-addition group) × 100
1-2. 1-2. ABTSABTS 라디칼 Radical 소거능Scatters
ABTS+ 라디칼 소거활성(radical scavenging)을 이용한 항산화 효과의 측정은 Van den Berg의 방법에 따라 측정하였다. 7 mM 2,2 아지노비스(3-에틸벤조티아졸린-6-설폰산(2,2 azinobis (3-ethylbenzothiazoline-6-sulfonic acid)와 2.4 mM 과황화칼륨(potassium persulfate)을 혼합하여 실온에서 24 시간 동안 방치하여 ABTS+ 라디칼을 형성시킨 후 99% 에탄올로 희석하여 사용하였다. 각 시료용액 100 μL에 희석한 ABTS+용액 100 μL넣고 암실에서 7 분 동안 반응시킨 후 734 nm 에서 흡광도를 측정하여 결과를 계산하였다.The antioxidative effect of ABTS + radical scavenging was measured by Van den Berg method. A mixture of 7
ABTS+ 라디칼 소거능(%) = (1-시료첨가군 흡광도/무첨가군 흡광도)×100ABTS + radical scavenging ability (%) = (1-absorbance group in the sample addition group / absorbance in the no-addition group) × 100
1-3. 총 폴리페놀 함량(total 1-3. Total polyphenol content (total polyphenolicpolyphenolic contents) 확인 contents)
폴리페놀 화합물의 정량은 Folin-danis법에 의해 측정하였다. 페놀 시약(Folin-Ciocalteu phenol reagent) 50 μL에 농도별로 희석한 시료용액 50 μL를 넣고 실온에서 3 min 동안 반응시키고 난 후 0.7 M 탄산나트륨(Na2CO3) 용액 50 μL를 넣은 뒤 암실에서 1 시간 동안 반응시키고 730 nm에서 흡광도를 측정한 후, 미리 작성한 표준물질 탄닌산(tannic acid)의 흡광도 그래프와 대비하여 폴리페놀 함량을 산출하였다.Quantification of polyphenol compounds was determined by the Folin-danis method. Add 50 μL of the diluted sample solution to 50 μL of phenol reagent (Folin-Ciocalteu phenol reagent), react at room temperature for 3 min, add 50 μL of 0.7 M sodium carbonate (Na 2 CO 3 ) solution, And the absorbance at 730 nm was measured. The polyphenol content was calculated in comparison with a previously prepared absorbance graph of a reference substance tannic acid.
2-1. 2-1. DPPHDPPH 라디칼 Radical 소거능Scatters 측정 결과 Measurement result
DPPH 라디칼은 보랏빛을 띄는 안정한 자유 라디칼의 일종으로 알코올 등의 유기용매에 매우 안정하며 항산화물질과 반응하면 양성자-라디칼 스캐빈저(proton-radical scavenger)에 의하여 노란빛으로 탈색되는 특징이 있으며 색변화에 의한 흡광도의 차이는 517 nm 부근에서 최대가 된다. 이 실험의 결과로 물질의 항산화 효과를 확인할 수 있고 비교적 간단한 방법을 사용하므로 항산화 활성을 검색하는데 많이 이용되고 있다. 칡 잎 추출물은 농도 의존적인 DPPH 소거능을 나타내어 항상화 효과가 확인되었으며 그 효과는 1,000 ㎍/mL 농도에서의 효과는 76% 이상으로 좋은 결과가 나타났다.The DPPH radical is a stable free radical which is very stable to organic solvents such as alcohol and reacts with antioxidants. It is characterized by decolorization by a proton-radical scavenger in yellow, The difference of the absorbance by 517 nm becomes maximum at around 517 nm. As a result of this experiment, the antioxidative effect of the substance can be confirmed and it is widely used to search for antioxidant activity by using a relatively simple method. Leaf extract showed a concentration - dependent DPPH elimination ability and the effect was constantly maintained. The effect was more than 76% at 1,000 ㎍ / mL concentration.
2-2. 2-2. ABTSABTS 라디칼 Radical 소거능Scatters 측정 결과 Measurement result
ABTS 양이온 라디칼은 청록빛을 띄는 라디칼의 일종으로 항산화 물질과 반응함에 따라 연한녹색으로 탈색이 되는 특징이 있다. 수소주는 항산화제(hydrogen-donating antioxidant)와 사슬 분해 항산화제(chain breaking antioxidant) 모두를 측정 할 수 있는 것으로 알려져 있으며 DPPH와 마찬가지로 비교적 손쉬운 실험방법으로 인해 일반적으로 많이 사용하고 있는 항산화능 측정 방법 중 하나이다. 칡 잎 추출물은 농도의존적인 ABTS 소거능을 나타내어 항산화 효과가 확인되었으며 그 효과는 1,000 ㎍/mL 농도에서의 94% 이상으로 나타났다.The ABTS cation radical is a type of cyanide radical that reacts with antioxidants and is characterized by discoloration by light green. Hydrogen is known to be able to measure both hydrogen-donating antioxidant and chain-breaking antioxidant, and it is one of the commonly used methods for measuring antioxidant capacity, as it is relatively easy to use as DPPH . The antioxidative effect of 칡 leaf extracts was demonstrated by the concentration dependent ABTS scavenging ability and its effect was over 94% at 1,000 ㎍ / mL concentration.
2-3. 총 폴리페놀 함량(total 2-3. Total polyphenol content (total polyphenolicpolyphenolic contents) 측정 결과 contents) measurement result
총 폴리페놀 화합물의 함량은 탄닌산(Tannic acid)을 이용한 표준 곡선을 이용하여 계산하였다. 칡 잎 추출물의 총 폴리페놀 함량은 58.56 mg TAE/g으로 나타났다. The content of total polyphenol compounds was calculated using a standard curve using tannic acid. Total polyphenol content of 칡 leaf extract was 58.56 mg TAE / g.
폴리페놀 화합물의 함량이 DPPH, ABTS 라디칼 소거능에 미치는 영향이 있다고 판단된다.The content of polyphenol compounds was found to have an effect on DPPH and ABTS radical scavenging ability.
[[ 실험예3Experimental Example 3 ] 칡 잎 추출물의 항염증 효과] Anti-inflammatory effect of 칡 leaf extract
1-1. 세포배양1-1. Cell culture
항염증 효과를 측정하기 위해 실험에 이용한 RAW 264.7 뮤린 대식세포(murine macrophage cell)의 배양은 10% FBS와 1% 페니실린/스트렙토마이신(penicillin/streptomycin) (100 unit/mL)을 첨가한 DMEM 배지를 사용하였으며 37 ℃, 5% 이산화탄소 항온기(CO2 incubator)에 적응시켜 계대 배양하였다.To determine the anti-inflammatory effect, RAW 264.7 murine macrophage cells were cultured in DMEM medium supplemented with 10% FBS and 1% penicillin / streptomycin (100 units / mL) And incubated at 37 ° C in a 5% CO 2 incubator (CO 2 incubator).
1-2. 칡 잎 추출물의 농도에 따른 세포 1-2. Cells according to the concentration of 칡 leaf extract 생존률Survival rate 측정 Measure
세포 생존률 측정은 Carmichael의 방법에 따라 측정하였다. 세포주 RAW 264.7을 96홈판(96 well plate)에 1 x 104 cells/well이 되도록 분배(seeding)하고 37 ℃, 5% 이산화탄소 항온기(CO2 incubator)에서 24 시간 동안 배양시킨다. 이후 혈청제거 배지로 교환하고 각 시료용액을 농도별로 처리한 뒤 37 ℃, 5% 이산화탄소 항온기 에서 24 시간 동안 배양시킨다. 대조군은 시료와 동량의 DMEM 배지를 첨가하여 같은 조건으로 배양하였다. 이후 5 mg/mL 농도로 제조한 MTT 용액 0.02 mL 첨가하여 4 h 동안 배양한 후 배양액을 제거하고 각 홈(well)당 다이메틸설폭시화물(dimethyl sulfoxide, DMSO) 0.1 mL를 넣어 실온에서 10 분 동안 반응 시킨 뒤 540 nm에서 흡광도를 측정하여 결과를 계산하였다.Cell viability was measured according to Carmichael's method. Cell line RAW 264.7 was seeded in 96 well plates at 1 x 10 4 cells / well and cultured in a 5% CO 2 incubator at 37 ° C for 24 hours. Subsequently, each sample solution was treated at different concentrations and incubated at 37 ° C in a 5
세포 생존률(%) = (시료첨가군 흡광도/무첨가군 흡광도)×100Cell viability (%) = (absorbance of sample group / absorbance of group without addition) x 100
1-3. 산화질소(Nitric oxide) 생성 억제 효능 측정1-3. Measuring the inhibitory effect of nitric oxide formation
Nitric oxide (NO) 생성량은 세포배양액에 존재하는 NO를 그리스 시약 시스템(griess reagent system)을 이용하여 측정하였다. 세포주 RAW 264.7을 96홈판(96 well plate)에 5 x 104 cells/well이 되도록 분배(seeding)하고 37 ℃, 5% 이산화탄소 항온기 에서 24 시간 동안 배양시킨다. 이후 혈청제거 배지로 교환하고 세포의 염증반응을 유도하기 위하여 지질다당류(lipopolysaccharide, LPS)를 1 ppm/well이 되도록 처리하고 각 시료용액을 농도별로 처리한 뒤 37 ℃, 5% 이산화탄소 항온기 에서 24 시간 동안 배양시킨다. 대조군은 시료와 동량의 DMEM 배지를 첨가하여 같은 조건으로 배양하였다. 이후 새로운 96 well plate에 세포 배양액을 100 μL 옮기고 그리스 시약(griess reagent)을 100 μL 첨가 하여 상온에서 5 분 동안 반응시킨 후에 540 nm에서 흡광도를 측정하여 결과를 계산하였다.The amount of nitric oxide (NO) produced was measured by using a griess reagent system. The cell line RAW 264.7 was seeded in a 96-well plate at 5 x 10 4 cells / well and cultured in a 5
NO 생성량(%) = (시료첨가군 흡광도/무첨가군 흡광도)×100NO production amount (%) = (absorbance of sample addition group / absorbance of no addition group) x 100
1-4. 1-4. iNOSiNOS , COX-2 단백질 발현 억제 효능 측정, The inhibitory effect of COX-2 protein expression
세포주 RAW 264을 96홈판(96 well plate)에 2 x 105 cells/well이 되도록 분배(seeding) 하고 37 ℃, 5% 이산화탄소 항온기 에서 24 시간 동안 배양시킨다. 이후 혈청제거 배지로 교환한 후 세포의 염증반응을 유도하기 위하여 지질다당류(lipopolysaccharide, LPS)를 1 ppm/well이 되도록 처리하고 각 시료용액을 농도별로 처리한 뒤 37 ℃, 5% 이산화탄소 항온기 에서 24 시간 동안 배양시킨다. 대조군은 시료와 동량의 DMEM 배지를 첨가하여 같은 조건으로 배양하였다. 이후 배지를 제거하고 PBS로 1회 세척 후 단백질분해효소 저해제(protease inhibitor)를 0.1% 함유시킨 RIPA 완충(buffer)를 60 μL/well로 처리하여 세포를 용해시키고 원심분리기(centrifuge)를 이용하여 4 ℃ 15,000 rpm에서 15 분 동안 원심분리 하였다. The cell line RAW 264 was seeded in a 96-well plate at 2 × 10 5 cells / well and cultured in a 5
원심분리 하여 얻은 상층액을 브래드포드 분석법(bradford assay)으로 정량하여 얻은 단백질 20 μL를 10% SDS-PAGE하여 분리시키고 전기 영동법(power supply electrophoresis)를 이용하여 PVDF 멤브레인(membrane)에 옮겨 디지털 왕복형 쉐이커(digital reciprocating shaker)를 이용하여 5% 스킨 밀크(skin milk), 1차 항체, 세척, 2차 항체, 세척 순서의 블로킹(blocking) 과정을 거친 다음 HRP 기질 시약으로 2 분 동안 반응시킨 후 웨스턴 이미지 시스템(western imaging system) 기기를 이용하여 밴드를 확인하고 결과를 산출하였다.The supernatant obtained by centrifugation was quantified by Bradford assay and 20 μL of the protein was separated by 10% SDS-PAGE and transferred to a PVDF membrane using a power supply electrophoresis, The cells were blocked with 5% skin milk, primary antibody, washing, secondary antibody and washing procedure using a digital reciprocating shaker, followed by reaction with HRP substrate reagent for 2 minutes, The band was identified using a western imaging system instrument and the results were calculated.
2-1. 칡 잎 추출물의 농도에 따른 세포 2-1. Cells according to the concentration of 칡 leaf extract 생존률Survival rate 측정 결과 Measurement result
대식세포(Macrophage cell)(RAW264.7)에 대한 칡 추출물의 농도별 처리에 따른 세포 생존률을 MTT 분석법(assay)을 통해 확인하였다. 칡 잎 추출물은 100 μg/mL 농도까지 안정적인 세포 생존률을 보였고 그 이상의 농도에서는 세포 생존률이 급격히 줄어드는 경향을 확인하였다. 따라서 Macrophage cell을 이용한 세포실험에서 사용가능한 칡 잎 추출물의 최고농도는 100 μg/mL로 설정하였다.The cell viability of macrophage cells (RAW264.7) was determined by MTT assay. Leaf extract showed stable cell viability up to 100 μg / mL and cell viability tended to decrease sharply. Therefore, the highest concentration of 칡 leaf extract available for cell experiments using macrophage cells was set at 100 μg / mL.
2-2. 산화질소(Nitric oxide) 생성 억제 효능 측정 결과2-2. Nitric oxide production inhibitory effect measurement result
LPS로 자극을 준 대식세포(Macrophage cell)(RAW264.7)에서 칡 추출물의 농도별 처리에 따른 산화질소 (NO) 생성 저해 효과를 측정하기 위해 칡 잎 추출물을 농도별로 세포에 처리하여 NO의 생성량을 측정하였다. 칡 잎 추출물의 세포 생존가능 최고 농도에서의 효과는 잎 54%로 나타나 효과적인 산화질소 생성 저해 효과가 있는 것으로 판단되었다.To determine the inhibitory effect of LPS- induced macrophage cells (RAW264.7) on the production of NO by nitric oxide (NO) treatment, Were measured. The effect of 칡 leaf extract on the cell viability of the highest concentration was 54%, indicating that it effectively inhibited the formation of nitrogen oxides .
2-2- 3.iNOS3. iNOS , COX-2 단백질 발현 억제 효능 측정 결과, The inhibitory effect of COX-2 protein expression
산화질소 저해활성 실험을 통해 얻은 항염증 효과를 검증하고 세포 내 단백질 단위에서 항염증 메커니즘을 알아보기 위해 Western blot 분석 실험을 진행하였다. 그 결과 칡 잎 추출물은 세포내 염증관련 단백질인 iNOS 와 COX-2의 생성을 매우 뛰어난 효과로 저해시키는 것으로 확인되었다. 사용가능 최고 농도인 100 μg/mL에서의 효과로 iNOS 단백질 생성을 약 99% 억제 시켰으며 COX-2 단백질은 약 98% 억제 시켰다. Western blot analysis was performed to examine the anti - inflammatory effect obtained from the nitric oxide inhibitory activity experiment and the anti - inflammatory mechanism in the intracellular protein unit. As a result, it was confirmed that the 칡 leaf extract inhibits the production of intracellular inflammation-related proteins iNOS and COX-2 with excellent effects. The effect at the highest available concentration of 100 μg / mL inhibited iNOS protein production by about 99% and COX-2 protein by about 98%.
<< 실시예Example 및 And 비교예Comparative Example >>
하기 [표 1] 의 조성으로 여드름용 에멀전을 당업계에 공지된 방법으로 제조하였다. 하기 [표 1] 의 단위는 중량% 이다. An emulsion for acne was prepared by a method known in the art in the composition of the following [Table 1]. The units in Table 1 below are% by weight.
[표 2] 에는 [표 1] 에 따른 제조법으로 만든 제형의 효과를 간략하게 나타내었다.[Table 2] briefly shows the effect of the formulation of the preparation method according to [Table 1].
◎ : 아주 좋다 / ○ : 좋다 / △ : 보통 / x : 효과없음⊚: very good / ∘: good / △: fair / x: no effect
[표 3] 의 항산화 효과의 측정은 DPPH 라디칼 소거능 측정법으로서 진행하였다. 실시예 및 비교예의 제형을 그대로 실험에 사용하였다.The antioxidant effect of [Table 3] was measured as a DPPH radical scavenging activity measurement method. The formulations of the Examples and Comparative Examples were used as they were.
[표 3]의 항균 효과의 측정은 평판 디스크(paper disc agar diffusion) 법으로서 진행하였으며 실시예 및 비교예의 제형을 0.5 mg/disc로 사용하여 나타난 생육저해환의 지를(mm)을 나타냈다. A는 표피포도상 구균(Staphylococcus epidermidis) 에 대한 결과이며 B는 프로피오니박테륨아크네스(Propionibacterium acnes)균에 대한 결과이다.The antimicrobial effect of [Table 3] was measured as a paper disc agar diffusion method, and the growth inhibition rings (mm) were shown using the formulations of Examples and Comparative Examples at 0.5 mg / disc. A is B is the result for Staphylococcus epidermidis and B is for Propionibacterium acnes.
[표 3]의 항염증 효과의 측정은 RAW264.7 대식세포에서 산화질소(Nitric oxide) 생성량 측정법으로서 진행하였다. 실시예 및 비교예의 제형을 1000배 희석하여 사용하였으며 샘플처리를 하지않은 군에 대비하여 생성된 산화질소 (Nitric oxide) 의 양을 %로 나타내었다.The anti-inflammatory effect of [Table 3] was measured as a measurement of nitric oxide production in RAW264.7 macrophages. The formulations of Examples and Comparative Examples were diluted 1000 times and the amount of nitric oxide produced in comparison with the untreated group was expressed as%.
(항산화 효과)DPPH radical scavenging ability
(Antioxidative effect)
(항균 효과)Growth inhibition ring size (mm)
(Antibacterial effect)
(항염증 효과)Nitric oxide production
(Anti-inflammatory effect)
[표 3] 은 본 발명 중 람노리피드 및 DOD 동시생성물 및 이에 칡 잎 추출물을 더한 실시예 1 및 2의 항산화, 항균, 항염증효과를 알 수 있었다.[Table 3] shows antioxidant, antibacterial and anti-inflammatory effects of Examples 1 and 2 in which the co-products of Ramanolipid and DOD in the present invention and the leaf extract thereof were added.
이하, 상기한 실험예의 결과를 근거로 하여 본 발명에 따른 물질의 사용에 관해 구체적으로 설명하기 위해 제형예로 [표 4] 내지 [표 9]를 들었다. 그러나, 이들 제형예는 어떠한 다른 비율과 형태로도 변형될 수 있으며, 본 발명의 범위가 아래에서 서술하는 제형예에 한정되는 것으로 해석되어서는 않는다는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명한 것이다. Hereinafter, [Table 4] to [Table 9] are given as formulation examples to specifically explain the use of the substance according to the present invention based on the results of the above experimental examples. It should be understood, however, by those skilled in the art that these formulation examples can be modified in any other proportions and forms, and that the scope of the present invention is not construed as being limited to the formulation examples described below It is.
Claims (12)
Antioxidant, antimicrobial, and anti-inflammatory agents containing Pseudomonas aeruginosa culture liquid extract containing Rhamnolipids and 7,10-dihydroxy-8 (E) -octadecenoic acid as active ingredients, A composition for improving acne.
칡 잎 추출물을 더 포함하는, 여드름 개선용 조성물.
The method according to claim 1,
A composition for improving acne, which further comprises a leaf extract.
상기 람노리피드 및 하이드록시 지방산을 포함하는 녹농균 배양액 추출물은 화학식 1로 표시되는 모노람노리피드(mono-rhamnolipids) 및 화학식 2로 표시되는 DOD(7,10-dihydroxy-8(E)-octadecenoic acid)를 동시에 포함하는 것을 특징으로 하는, 여드름 개선용 조성물:
[화학식 1]
[화학식 2]
3. The method according to claim 1 or 2,
The extract of Pseudomonas aeruginosa culture solution containing the above-mentioned rhamnoglyphides and hydroxy fatty acids is prepared by mixing mono-rhamnolipids represented by the formula (1) and DOD (7,10-dihydroxy-8 (E) -octadecenoic acid The composition for ameliorating acne characterized by comprising:
[Chemical Formula 1]
(2)
상기 여드름 개선용 조성물이 표피포도상 구균(Staphylococcus epidermidis) 또는 프로피오니박테륨아크네스(Propionibacterium acnes)에 대하여 항균 활성을 나타내는 것을 특징으로 하는, 여드름 개선용 조성물.
3. The method according to claim 1 or 2,
Wherein the composition for improving acne has an antibacterial activity against Staphylococcus epidermidis or Propionibacterium acnes.
상기 람노리피드 및 하이드록시지방산을 1: 0.1 내지 0.8의 중량비로 포함하는, 여드름 개선용 조성물.
The method according to claim 1,
A composition for improving acne, which comprises the rhamnolipid and the hydroxy fatty acid at a weight ratio of 1: 0.1 to 0.8.
상기 여드름 개선용 조성물은 당해 조성물의 전체 중량을 기준으로 0.001 내지 20 중량부의 함량으로 포함하는, 여드름 개선용 조성물.
6. The method of claim 5,
Wherein the composition for improving acne contains 0.001 to 20 parts by weight based on the total weight of the composition.
상기 녹농균 배양액 추출물과 칡 잎 추출물의 사용 비율은 1: 0.5 내지 30의 중량비 범위인 것을 특징으로 하는, 여드름 개선용 조성물.
3. The method of claim 2,
Wherein the use ratio of the Pseudomonas aeruginosa culture solution extract to the Leaf extract is in a weight ratio of 1: 0.5 to 30.
상기 여드름 개선용 조성물은 당해 조성물의 전체 중량을 기준으로 0.001 내지 20 중량부의 함량으로 포함되는 것을 특징으로 하는, 여드름 개선용 조성물.
8. The method of claim 7,
Wherein the composition for improving acne is contained in an amount of 0.001 to 20 parts by weight based on the total weight of the composition.
상기 여드름 개선용 조성물은 여드름 개선용 화장료 조성물 것을 특징으로 하는, 여드름 개선용 조성물.
3. The method according to claim 1 or 2,
Wherein the composition for improving acne is a composition for improving acne.
상기 여드름 개선용 조성물은 여드름 개선용 피부외용제 조성물인 것을 특징으로 하는, 여드름 개선용 조성물.
3. The method according to claim 1 or 2,
Wherein the composition for improving acne is a composition for external application for skin for improving acne.
상기 여드름 개선용 조성물은 여드름 개선용 식품 조성물인 것을 특징으로 하는, 여드름 개선용 조성물.
3. The method according to claim 1 or 2,
Wherein the composition for improving acne is a composition for improving acne.
상기 여드름 개선용 조성물은 용액, 현탁액, 유탁액, 페이스트, 겔, 졸, 크림, 로션, 파우더, 비누, 클렌징 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이로 이루어진 군으로부터 선택되는 제형을 갖는, 여드름 개선용 조성물.
The method of claim 9, wherein
The composition for improving acne has a formulation selected from the group consisting of solution, suspension, emulsion, paste, gel, sol, cream, lotion, powder, soap, cleansing oil, powder foundation, emulsion foundation, wax foundation and spray , A composition for improving acne.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170058923A KR20180124432A (en) | 2017-05-11 | 2017-05-11 | Composition for improving acne with antioxidant, antibacterial and anti-inflammatory properties |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170058923A KR20180124432A (en) | 2017-05-11 | 2017-05-11 | Composition for improving acne with antioxidant, antibacterial and anti-inflammatory properties |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20180124432A true KR20180124432A (en) | 2018-11-21 |
Family
ID=64602179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170058923A Withdrawn KR20180124432A (en) | 2017-05-11 | 2017-05-11 | Composition for improving acne with antioxidant, antibacterial and anti-inflammatory properties |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20180124432A (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110742819A (en) * | 2019-12-10 | 2020-02-04 | 广州瑞誉化工科技有限公司 | Amino acid facial cleansing honey |
KR20200082268A (en) | 2018-12-28 | 2020-07-08 | 건국대학교 글로컬산학협력단 | compositions containing fermented extract of Panax ginseng |
KR20210101843A (en) | 2020-02-11 | 2021-08-19 | 선문대학교 산학협력단 | 6,7-dihydroxy coumarin Anti inflammatory Composition |
KR20210107375A (en) | 2020-02-24 | 2021-09-01 | 선문대학교 산학협력단 | Anti inflammatory Composition by 6,7-dihydroxy coumarin and Micro organism |
CN116286543A (en) * | 2023-04-14 | 2023-06-23 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | Staphylococcus epidermidis with good moisturizing, whitening, anti-inflammatory, antioxidant and anti-aging effects and application thereof |
FR3132638A1 (en) * | 2022-02-17 | 2023-08-18 | L'oreal | Use of rhamnolipid(s) to prevent staining of cutaneous blackheads |
WO2024076921A1 (en) * | 2022-10-03 | 2024-04-11 | Stepan Company | Method and composition for controlling acne using rhamnolipids |
CN118662408A (en) * | 2024-06-03 | 2024-09-20 | 广州嘉瑞新材料有限公司 | Ginseng and barberry acne removing mixture, preparation method and application thereof in cosmetics |
-
2017
- 2017-05-11 KR KR1020170058923A patent/KR20180124432A/en not_active Withdrawn
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200082268A (en) | 2018-12-28 | 2020-07-08 | 건국대학교 글로컬산학협력단 | compositions containing fermented extract of Panax ginseng |
CN110742819A (en) * | 2019-12-10 | 2020-02-04 | 广州瑞誉化工科技有限公司 | Amino acid facial cleansing honey |
CN110742819B (en) * | 2019-12-10 | 2023-04-25 | 广州瑞誉化工科技有限公司 | Amino acid facial cleaning honey |
KR20210101843A (en) | 2020-02-11 | 2021-08-19 | 선문대학교 산학협력단 | 6,7-dihydroxy coumarin Anti inflammatory Composition |
KR20210107375A (en) | 2020-02-24 | 2021-09-01 | 선문대학교 산학협력단 | Anti inflammatory Composition by 6,7-dihydroxy coumarin and Micro organism |
FR3132638A1 (en) * | 2022-02-17 | 2023-08-18 | L'oreal | Use of rhamnolipid(s) to prevent staining of cutaneous blackheads |
WO2023156588A1 (en) * | 2022-02-17 | 2023-08-24 | L'oreal | Use of rhamnolipid(s) for preventing the colouration of cutaneous blackheads |
WO2024076921A1 (en) * | 2022-10-03 | 2024-04-11 | Stepan Company | Method and composition for controlling acne using rhamnolipids |
CN116286543A (en) * | 2023-04-14 | 2023-06-23 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | Staphylococcus epidermidis with good moisturizing, whitening, anti-inflammatory, antioxidant and anti-aging effects and application thereof |
CN116286543B (en) * | 2023-04-14 | 2023-07-21 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | Staphylococcus epidermidis with good moisturizing, whitening, anti-inflammatory, anti-oxidative and anti-aging effects and its application |
CN118662408A (en) * | 2024-06-03 | 2024-09-20 | 广州嘉瑞新材料有限公司 | Ginseng and barberry acne removing mixture, preparation method and application thereof in cosmetics |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20180124432A (en) | Composition for improving acne with antioxidant, antibacterial and anti-inflammatory properties | |
KR100847103B1 (en) | Fermented guava composition and use thereof | |
KR102166279B1 (en) | Composition for Anti-Oxidant, Anti-Bacterial and Anti-Inflammatory Effect Comprising Plant Complex Extracts as Active Ingredient | |
WO2018084112A1 (en) | Acne strain-selective antibacterial agent | |
KR101634668B1 (en) | Cosmetic composition comprising fermented extract of mistletoe for anti-oxidation or whitening | |
KR102065185B1 (en) | Composition for Improving Skin Conditions with Improved Anti-Bacterial, Anti-inflammatory, Anti-wrinkling, and Skin Whitening Property | |
KR102247810B1 (en) | Composition Comprising Mixed Culture Strain of Lactobacillus sp. SDCM 1003 and SDCM 1105, Culture Fluid, or Culture Fluid Extract thereof as Active Ingredient | |
KR20120058850A (en) | Compositions for the antiinflammatory and the antimicrobial activities | |
KR101637167B1 (en) | Antibacterials composition comprising Sedum extract composition and food additives and preparation method thereof | |
TWI535449B (en) | Use of plectranthus amboinicus extract for preparing anti-acne composition | |
KR101495272B1 (en) | Compositions containing 3-(dodecanoyloxy)-2-(isobutyryloxy)-4-methylpentanoic acid As Active Ingredients | |
KR100971269B1 (en) | Processed thick gourd extract and antimicrobial composition containing the same | |
KR20100007122A (en) | Anti-bacterial or anti-fungal composition | |
KR101433823B1 (en) | External Composition for Skin Using an Extract or a Fraction of Padina arborescens | |
KR102158134B1 (en) | Antibacterial composition comprising an extract of schisandra chinesis | |
KR20130112322A (en) | Antimicrobial activity and anti-inflammatory effect composition comprising extract of capsella species as an effective ingredient | |
KR102465358B1 (en) | A preservative for skin external application comprising magnolol, honokiol, or a combination thereof, and a cosmetic composition comprising the same | |
KR101839612B1 (en) | Natural Preservative Composition Containing Plant Extract Complex as Active Ingredient | |
KR102252855B1 (en) | Cosmetic composition comprising nano-ized lactobacillus genus dead cells and a method for producing the same | |
KR101507533B1 (en) | Natural preservative composition containing Silver Needle White Tea Extract, Magnolia Obovata Bark Extract and Terminalia Chebula Bark Extract | |
KR102009604B1 (en) | Antimicrobial composition comprising lonicera japonica extract and magnolia obovata extract | |
KR20150050631A (en) | Cosmetic Composition and Topical Composition for Anti-inflammation Containing Coprisin Peptide Derivative CopA | |
KR20230080174A (en) | Composition for anti-oxidation, anti-inflammation, and acne comprising extracts unripe fruit derived from Poncirus trifoliata | |
KR101803148B1 (en) | An antibacterial composition comprising the extract or fraction of Sargassum serratifolium | |
KR20210020817A (en) | Antimicrobial composition against acne-inducing bacteria comprising extract of Garcinia mangostana L., and formulation for preventing or treating acne comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20170511 |
|
PG1501 | Laying open of application | ||
PC1203 | Withdrawal of no request for examination |